We'd love to hear from you with your ideas, suggestions for topics/guests, shoutouts to colleagues or mentors, questions for Dr. Henry or Dr. Yurkiewizc. To get in touch, please email us at podcasts@mdedge.com or follow us on Twitter @MDedgeHemOnc.
In this episode, Alok Khorana, MD, of the Cleveland Clinic joins David H. Henry, MD, to discuss results from the CASSINI trial and what it means for anticoagulation in cancer patients.
And Ilana Yurkiewicz, MD, begins part 1 of her look at informed consent.
Scroll down for show notes and references
Show notes
By Hitomi Hosoya, MD, PhD
Resident in the department of internal medicine, University of Pennsylvania Health System
- One in five cancer patients develop venous thromboembolism (VTE).
- The Khorana scoring system was developed and validated to stratify the VTE risk in cancer patients. The score is determined by the type of cancer, complete blood counts, and BMI.
- The CASSINI trial was aimed at determining the efficacy of oral factor Xa inhibitor for thromboprophylaxis in ambulatory patients with cancer who had a Khorana score of 2 or greater and were initiating chemotherapy.
- In total, 4.5% of the potential cohort had deep vein thrombosis (DVT) at screening ultrasound and were excluded from the study.
- The trial showed that rivaroxaban led to a substantially lower incidence of VTE, compared with the placebo group during the intervention period.
References:
Blood. 2008 May 15;111(10):4902-7. Cancer. 2012 Jul 15;118(14):3468-76. N Engl J Med. 2019 Feb 21;380(8):720-8.